08:33 AM EDT, 08/07/2025 (MT Newswires) -- (Update with Novo Nordisk's ( NVO ) premarket stock price in the last paragraph.)

Eli Lilly ( LLY ) said Thursday its experimental orforglipron oral glucagon-like peptide-1 lowered weight by an average of 12.4%, or 27.3 pounds, with a 36-milligram dose, in adults who are obese or overweight with a weight-related medical problem and without diabetes in a phase 3 trial.

Study participants who received a placebo lowered their weight by an average of 0.9%.

The company said all three doses of orforglipron met the primary endpoint and all key secondary endpoints, compared with placebo, at 72 weeks.

Treatment discontinuation rates due to adverse events ranged from 5.1% to 10.3% for various doses of orforglipron versus 2.6% with placebo, the company said.

Lilly's shares fell 7.1% in recent Thursday premarket activity, while Novo Nordisk's ( NVO ) stock rose 8%.